CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 21-231

PHARMACOLOGY REVIEW(S)

JUN 23 2000

NDA 21-231

Sto Izenberg

REVIEW AND EVALUATION OF PHARMACOLOGY AND TOXICOLOGY DATA
Original Summary

Sidney J. Stolzenberg
June 23, 2000

ORIGINAL NDA DATED: April 14, 2000
CENTER RECEIPT DATE: April 17, 2000
REVIEWER RECEIPT DATE: April 28, 2000

SPONSOR: Astra Zeneca Pharmaceuticals LP
1800 Concord Pike
P.O. Box 15437
Wilmington, DE 19850-5437
Telephone: 302-886-7539 (Judy W. Firor)
FAX: 301-886-2822

DRUG: ZOMIG-ZMT™ (zolmitriptan) Orally Disintegrating Tablets



MW: 287.36

FORMULATION: 2.5 mg [redacted]

Excipients per tablet include mannitol, microcrystalline cellulose, crospovidone, aspartame, sodium bicarbonate, anhydrous citric acid, colloidal silicon dioxide, magnesium stearate and orange flavor.

PHARMACOLOGICAL CLASS: Serotonin receptor subtype 5-$HT_{1B/1D}$ partial agonist

PROPOSED INDICATION: / [redacted]

DOSAGE REGIMEN: One 2.5 [redacted]

RELATED APPLICATIONS: IND 55,960 for ZOMIG-ZMT™ (zolmitriptan) Orally Disintegrating Tablets, NDA 20-768 & IND 45,147 for ZOMIG™ (zolmitriptan) Tablets

RELATED COMPOUNDS: IMITREX® (sumatriptan succinate)

BACKGROUND: NDA 20-768 for ZOMIG (zolmitriptan) tablets was approved on 11/26/97. It is currently marketed for the treatment of migraine with or without aura in adults. The present NDA application provides evidence for the efficacy and safety for the use of the formulation for ZOMIG-ZMT. It has been previously agreed that the existing preclinical data for ZOMIG is sufficient to support the present NDA for ZOMIG-ZMT (pre-NDA teleconference of 1/14/00 and meeting on 2/10/00)). All excipients, except orange flavor, conform to USP/NF requirements, but [redacted] . The issue of aspartame interaction with the drug and/or excipients has been resolved. (See review of Chemistry, Manufacturing and Controls in IND 55,960 by M. Heiman, PhD, dated 7/1/98).

LABELING: All sections pertaining to pre-clinical pharmacology and toxicology are identical to that for ZOMIG. There are no further recommendations.

CONCLUSION AND RECOMMENDATION: There are no objections from pharmacology for approval of this NDA.

/S/
Sidney J. Stolzenberg, PhD

cc:
HFD-120 Division File
HFD-120/LChen
HFD-120/Gfitzgerald ggg 7/12/00
HFD-120/AOliva
HFD-120/SStolzenberg
NDA21-231.rv1